Medical Progress Today
mpt home | sign up

Volume 4, Number 17
May 25, 2007


PRINTER FRIENDLY

Commentary

Canadian media needle Sicko

Peter Howell, Toronto Star, 5-20-07

Howell, reporting from Cannes, writes that Michael Moore's mockumentary on American health care, Sicko, is receiving a chilly reception from Canadian journalists who question his rose–colored depiction of Canadian health care.

We Canucks were taking issue with the large liberties Sicko takes with the facts, with its lavish praise for Canada's government–funded medicare system compared with America's for–profit alternative.

While justifiably demonstrating the evils of an American system where dollars are the major determinant of the quality of medicare care a person receives, and where restoring a severed finger could cost an American $60,000 compared to nothing at all for a Canadian, Sicko makes it seem as if Canada's socialized medicine is flawless and that Canadians are satisfied with the status quo.

Moore makes the eyebrow–raising assertion that Canadians live on average three years longer than Americans because of their superior health care system.

We Canucks were taking issue with the large liberties Sicko takes with the facts, with its lavish praise for Canada's government–funded medicare system compared with America's for-profit alternative.

We might hear even more criticism of Moore's film from Cuban patients...if they were ever allowed to leave Castro's dictatorship.

Source: http://www.thestar.com/artsentertainment/article/215801


Medical Progress Today is published by the Center for Medical Progress at the Manhattan Institute for Policy Research.

For more information about Medical Progress Today, please contact the managing editor, Paul Howard, at phoward@manhattan-institute.org, or via telephone at 212.599.7000.

Press inquiries regarding Medical Progress Today can be directed to the Communications Department, at communications@manhattan-institute.org, or via telephone at 212.599.7000.

If you would like to unsubscribe, please reply to us and type "Unsubscribe" in the subject line.

In this week's issue:

news

For drug makers, a downside to full disclosure
Lawyers forecast a flood of Avandia litigation
Avandia concerns reopen a wider debate

commentary

Rosiglitazone and Cardiovascular Risk
We’re seeking more data: FDA protects public health with careful analysis, not snap judgments
Canadian media needle Sicko
Does a drug firms free lunch influence doctors?
Doctors, drugs, and the poor
Sometimes, what’s needed is a nudge

research

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Center for Medical Progress 
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000
mpt@manhattan-institute.org